NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
Accelerate tech commercialization for heart, lung, blood, and sleep disorders through Phase IIB awards promoting partnerships with investors.
This grant is no longer accepting proposals
National Institutes of Health has archived this opportunity.
Funder: National Institutes of Health (NIH)
Due Dates: November 17, 2025
Funding Amounts: No specified ceiling or floor; award size and duration depend on project needs and third-party funding; matching funds from third-party investors are required.
Summary: Supports later-stage (Phase IIB) SBIR projects to accelerate commercialization of heart, lung, blood, and sleep disorder technologies, bridging the gap between Phase II funding and regulatory approval.
Key Information: Applicants must secure third-party investment funds equal to or greater than the NHLBI request.
Description
This opportunity, offered by the National Heart, Lung, and Blood Institute (NHLBI) at NIH, invites Small Business Innovation Research (SBIR) Phase IIB Bridge Award applications. The program aims to facilitate the commercialization of innovative technologies addressing heart, lung, blood, and sleep disorders. It specifically targets projects that have completed SBIR or STTR Phase II funding and require additional support to advance products toward regulatory approval and market entry. The program prioritizes projects that have strong third-party investment commitments and a clear pathway to clinical impact.
